ANDA 75979, held by Watson Labs. Metformin Hydrochloride.
As of Nov 16, 2026, ANDA 75979 (Metformin Hydrochloride), held by Watson Labs, was first approved by FDA on Jan 24, 2002, with 9 approved supplements and 0 published complete response letters.
| Date | Submission | Status | Documents |
|---|---|---|---|
| Jan 24, 2002 | Original application | Approved | None posted |
| Metformin Hydrochloride500MG · tablet;oral | Metformin Hydrochloride | Discontinued |
| Metformin Hydrochloride850MG · tablet;oral | Metformin Hydrochloride | Discontinued |
| Metformin Hydrochloride1GM · tablet;oral | Metformin Hydrochloride | Discontinued |
| Aug 11, 2026 | Supplement 19Labeling · Standard review | Approved | None posted |
| Jul 14, 2026 | Supplement 17Labeling · Standard review | Approved | None posted |
| Jul 14, 2026 | Supplement 18Labeling · Standard review | Approved | None posted |
| Mar 4, 2005 | Supplement 10Labeling | Approved | None posted |
| Apr 1, 2004 | Supplement 9Labeling | Approved | None posted |
| Feb 27, 2003 | Supplement 3Labeling | Approved | None posted |
| Oct 11, 2002 | Supplement 5Manufacturing | Approved | None posted |
| Aug 13, 2002 | Supplement 6Labeling | Approved | None posted |
| Apr 22, 2002 | Supplement 4Labeling | Approved | None posted |
| Jan 24, 2002 | Original application | Approved | None posted |
Approvals, supplements, products and documents come from FDA's Drugs@FDA data files, refreshed daily; Drugs@FDA lists approved applications only. Complete response letters are FDA's published letters. Drugs@FDA and FDA complete response letters